AstraZeneca $1.2bn collaboration expands metabolic footprint
AstraZeneca has significantly expanded its footprint in the metabolic disease market by entering into a strategic collaboration with Hong Kong-based CSPC Pharmaceutical Group. The landmark agreement, announced on January 30, focuses on the development of eight next-generation programs for obesity and type 2 diabetes, leveraging CSPC’s advanced AI-driven peptide discovery platform and proprietary LiquidGel monthly dosing technology. Under the financial…